Home
Storia in 1 fonti
Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibiotic
Wockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial results and the drugs potential to treat severe drug-resistant infections boosted investor sentiment, helping the stock extend recent gains despite technically entering overbought territory after a sharp rally.
Raccontata da
economictimes.indiatimes.com
Timeline cronologica
- ·
Wockhardt gets CDSCO nod for Zaynich antibiotic
Wockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to treat complicated urinary tract infections…
- ·
Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibiotic
Wockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial results and the drugs potential to treat…
- ·
Wockhardt secures US FDA approval for antibiotic Zaynich
Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs…
- ·
FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market
Wockhardts newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug.…
- ·
Wockhardt shares in focus after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt will be in focus after the US FDA approved ZAYNICH, a novel intravenous antibiotic combining cefepime and zidebactam for complicated urinary tract infections. The drug…